. 2021 Apr 26;16(4):e0250642. doi: 10.1371/journal.pone.0250642

Table 2. Clinic-pathological features of non-IBC and IBC patients.

Group Characteristics		non-IBC	IBC	p-value
Group Characteristics		n = 34	n = 23	p-value
Age (Years)	Range	25–70	36–71	0.23 ^a
Age (Years)	Mean (SEM)	47.41 ± 0.11	51.72 ± 0.15	0.23 ^a
Tumor Size (cm), n%	≥4	19 (56)	14 (61)	0.60 ^b
Tumor Size (cm), n%	< 4	15 (44)	9 (39)	0.60 ^b
Tumor Grade, n%	I	3 (9)	2 (9)	0.75 ^b
	II	24 (71)	17 (74)
	III	7 (21)	4 (17)
Tumor Stage	I and II	24 (71)	0	< 0.0001^b
Tumor Stage	III	10 (29)	23 (100)	< 0.0001^b
Lymphovascular Invasion, n%	Positive	13 (38)	12 (52)	0.20 ^b
Lymphovascular Invasion, n%	Negative	21 (62)	11 (48)	0.20 ^b
Lymph Nodes, n%	≥4	15 (44)	12 (52)	0.21 ^b
Lymph Nodes, n%	< 4	19 (56)	11 (48)	0.21 ^b
ER, n%	Positive	23 (68)	13 (57)	0.41 ^b
	Negative	11 (32)	9 (39)
	NA	0	1 (4)
PR, n%	Positive	24 (71)	12 (52)	0.18 ^b
	Negative	10 (29)	10 (43)
	NA	0	1 (4)
Her-2, n%	Positive	10 (29)	10 (43)	0.15 ^b
	Negative	24 (71)	12 (52)
	NA	0	1 (4)

Data are expressed as mean ± SEM, NA Data not available

* Significant p value calculated by ^aStudent’s t-test or ^bPearson Chi-Square. ER, estrogen receptor; PR, progesterone receptor; Her-2, human epidermal growth factor receptor-2.